Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: A phase III study in Tanzania
| dc.contributor.author | Laheya, T. | |
| dc.contributor.author | Arbeitb, R.D. | |
| dc.contributor.author | Bakaric, M. | |
| dc.contributor.author | Horsburgh, C.R. | |
| dc.contributor.author | Mateec, M. | |
| dc.contributor.author | Waddella, R. | |
| dc.contributor.author | Mteic, L. | |
| dc.contributor.author | Vuolae, J.M. | |
| dc.contributor.author | Pallangyoc, K. | |
| dc.contributor.author | Reyna, C.F. | |
| dc.date.accessioned | 2013-02-11T07:04:05Z | |
| dc.date.available | 2013-02-11T07:04:05Z | |
| dc.date.issued | 2010 | |
| dc.description.abstract | Preventive immunization with whole inactivated Mycobacterium vaccae (MV) confers protection against HIV-associated tuberculosis (TB) in BCG-immunized adults with CD4 counts ≥200 cells/ l. We evaluated the immunogenicity of MV in the 2013 subjects of the phase III DarDarTrial using an interferon gamma (IFN- ) enzyme linked immunosorbent assay (ELISA), tritiated thymidine lymphocyte proliferation assay (LPA) and an ELISA for antibodies to the TB glycolipid lipoarabinomannan (LAM).MVimmunization boosts IFN- and LPA responses to MV sonicate, and antibody responses to LAM. Post-immunization immune responses to MV correlated with baseline clinical factors, but the responses did not predict protection from HIV-associated TB. | en_GB |
| dc.identifier.issn | 2010 | |
| dc.identifier.uri | http://hdl.handle.net/123456789/247 | |
| dc.language.iso | en | en_GB |
| dc.publisher | ELSEVIER | en_GB |
| dc.relation.ispartofseries | Vaccine;doi:10.1016/j.vaccine.2010.09.041 | |
| dc.subject | Tuberculosis | en_GB |
| dc.subject | HIV | en_GB |
| dc.subject | Vaccines | en_GB |
| dc.subject | Interferons | en_GB |
| dc.subject | Cell proliferation | en_GB |
| dc.title | Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: A phase III study in Tanzania | en_GB |
| dc.type | Article | en_GB |